| CNS | Central nervous system |
| CSF | Cerebrospinal fluid |
| DMF | Dimethyl fumarate |
| DMT | Disease modifying treatment |
| EBV | Epstein Barr Virus |
| EAE | Experimental autoimmune encephalomyelitis |
| FGF | Fibroblast growth factor |
| FGFR | Fibroblast growth factor receptor |
| LINGO-1 | Leucine rich repeat and immunoglobin-like domain-containing protein 1 |
| mTOR | Mammalian target of rapamycin |
| MAPK | Mitogen-activated protein kinase |
| Myrf | Myelin Regulatory Factor |
| ERK | Extracellular signal-regulated kinases |
| MS | Multiple sclerosis |
| MOG | Myelin oligodendrocyte glycoprotein |
| OPCs | Oligodendrocyte progenitor cells |
| PROs | Patient-reported outcomes |
| PLC | Phospholipase C |
| PML | Progressive multifocal leukoencephalopathy |
| PKB/Akt | Protein kinase B |
| RRMS | Relapsing remitting multiple sclerosis |
| SEMA3A | Semaphorin 3A |
| STAT | Signal transducer and activator of transcription |
| S1P | Sphingosine 1-phosphate |
| TGF-β | Transforming growth factor beta |
| VLA-4 | Very late antigen-4 |